NeuroStar Partners With This Is My Brave to Recognize Teen Mental Health Month
New initiative aims to provide information and resources for teen mental health amidst rising public health concernsMALVERN, Pa., Aug. 01,...
New initiative aims to provide information and resources for teen mental health amidst rising public health concernsMALVERN, Pa., Aug. 01,...
NEW YORK, July 31, 2024 /PRNewswire/ -- The global diagnostic wearable medical devices market size is estimated to grow by USD...
Empathetics unveils new white paper BOSTON, July 30, 2024 /PRNewswire/ -- Empathetics, Inc. the pioneer in empathy training in healthcare,...
PHILADELPHIA, July 30, 2024 /PRNewswire/ -- uMethod Health, a pioneer in personalized cognitive care planning, has announced that it is...
MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for...
NEW HAVEN, Conn., July 30, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence...
The esteemed annual symposium explores the most urgent questions facing our future BOSTON, July 29, 2024 /PRNewswire/ -- The Chopra...
AAIC Poster Presentation Highlights XPro's™ Significant Effects on a Wide Range of Synaptic Proteins and Pathways BOCA RATON, Fla., July...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
This data supports the potential of plasma ASC levels as a biomarker for early stages of cognitive decline, based on...
PURCHASE, N.Y., July 26, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage...
Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose...
$30.3 million financing upfront with up to an additional $92.4 million tied to exercise of warrants, with certain of the...
If approved, Yuvanci® would become the only single tablet combination for treatment for patients with PAH Johnson & Johnson’s comprehensive...
Ipsen receives CHMP positive opinions for Iqirvo® (elafibranor) in Primary Biliary Cholangitis and Kayfanda® (odevixibat) in Alagille Syndrome, two rare...
- Demonstrates Neurophet AQUA AD for AD treatments such as Leqembi and Kisunla - Introduces updated version of Neurophet SCALE...
Nerivio, currently indicated for use in ages 12 and older, demonstrates study results in younger children with migraine. BRIDGEWATER, N.J. and...
Life sciences platform enhanced to make cognitive assessments easier and more precise BOSTON, July 24, 2024 /PRNewswire/ -- Linus Health, a...
Company's virtual therapeutic programs and proprietary risk stratification algorithm support proactive detection of and intervention for cognitive decline BOSTON, July...